Press release
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
DelveInsight's, "Small Lymphocytic Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Small lymphocytic lymphoma Pipeline Report
* DelveInsight's Small lymphocytic lymphoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Small lymphocytic lymphoma treatment.
* The leading Small lymphocytic lymphoma Companies working in the market include Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
* Promising Small lymphocytic lymphoma Therapies in the various stages of development include ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
* May 2024:- Juno Therapeutics, a Subsidiary of Celgene- An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004). This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose.
* May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010).
* May 2024:- Inhye Ahn- A Phase 2 Study of Fixed Duration Therapy With Pirtobrutinib and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (POP). This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Request a sample and discover the recent advances in Small lymphocytic lymphoma @ Small lymphocytic lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Small lymphocytic lymphoma Overview
SLL is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood.
Small lymphocytic lymphoma treatment may involve the use of low or high intensity combination chemotherapy, more recently with a targeted therapy such as a monoclonal antibody. This is commonly known as chemo immunotherapy. The combination of drugs will depend on age, stage of disease and risk factors. Small lymphocytic lymphoma that accumulates in the bone marrow and the spleen can deplete the amount of healthy blood cells in the circulating blood (blood that flows throughout the body).
Small lymphocytic lymphoma Emerging Drugs Profile
* TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
TQ-B3525 is a novel and selective oral PI3K / inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K and PI3K in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.
* LOXO-305: Loxo Oncology
Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, and marginal zone lymphoma.
* IOV 2001: Iovance Biotherapeutics
IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.
Learn more about Small lymphocytic lymphoma in clinical trials @ Small lymphocytic lymphoma Drugs [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Small lymphocytic lymphoma Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.
DelveInsight's Small lymphocytic lymphoma pipeline report covers around 80+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Discover more about Small lymphocytic lymphoma in development @ Small lymphocytic lymphoma Clinical Trials [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Small lymphocytic lymphoma Companies
Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Small lymphocytic lymphoma Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
To know more about Small lymphocytic lymphoma, visit @ Small lymphocytic lymphoma Segmentation [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Small lymphocytic lymphoma Pipeline Report
* Coverage- Global
* Small lymphocytic lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Small lymphocytic lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Small lymphocytic lymphoma Companies- Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
* Small Lymphocytic Lymphoma Therapies- ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
For further information on the Small lymphocytic lymphoma Pipeline Therapeutics, reach out @ Small lymphocytic lymphoma Products Development [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Small Lymphocytic Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Small Lymphocytic Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Last Stage Products (Phase III)
* LOXO-305: Loxo Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Small Lymphocytic Lymphoma Key Companies
* Small Lymphocytic Lymphoma Key Products
* Small Lymphocytic Lymphoma - Unmet Needs
* Small Lymphocytic Lymphoma - Market Drivers and Barriers
* Small Lymphocytic Lymphoma - Future Perspectives and Conclusion
* Small Lymphocytic Lymphoma Analyst Views
* Small Lymphocytic Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=small-lymphocytic-lymphoma-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Key Takeaways from the Small lymphocytic lymphoma Pipeline Report
* DelveInsight's Small lymphocytic lymphoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Small lymphocytic lymphoma treatment.
* The leading Small lymphocytic lymphoma Companies working in the market include Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
* Promising Small lymphocytic lymphoma Therapies in the various stages of development include ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
* May 2024:- Juno Therapeutics, a Subsidiary of Celgene- An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004). This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose.
* May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010).
* May 2024:- Inhye Ahn- A Phase 2 Study of Fixed Duration Therapy With Pirtobrutinib and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (POP). This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Request a sample and discover the recent advances in Small lymphocytic lymphoma @ Small lymphocytic lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Small lymphocytic lymphoma Overview
SLL is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood.
Small lymphocytic lymphoma treatment may involve the use of low or high intensity combination chemotherapy, more recently with a targeted therapy such as a monoclonal antibody. This is commonly known as chemo immunotherapy. The combination of drugs will depend on age, stage of disease and risk factors. Small lymphocytic lymphoma that accumulates in the bone marrow and the spleen can deplete the amount of healthy blood cells in the circulating blood (blood that flows throughout the body).
Small lymphocytic lymphoma Emerging Drugs Profile
* TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
TQ-B3525 is a novel and selective oral PI3K / inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K and PI3K in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.
* LOXO-305: Loxo Oncology
Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, and marginal zone lymphoma.
* IOV 2001: Iovance Biotherapeutics
IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.
Learn more about Small lymphocytic lymphoma in clinical trials @ Small lymphocytic lymphoma Drugs [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Small lymphocytic lymphoma Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.
DelveInsight's Small lymphocytic lymphoma pipeline report covers around 80+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Discover more about Small lymphocytic lymphoma in development @ Small lymphocytic lymphoma Clinical Trials [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Small lymphocytic lymphoma Companies
Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Small lymphocytic lymphoma Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
To know more about Small lymphocytic lymphoma, visit @ Small lymphocytic lymphoma Segmentation [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Small lymphocytic lymphoma Pipeline Report
* Coverage- Global
* Small lymphocytic lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Small lymphocytic lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Small lymphocytic lymphoma Companies- Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
* Small Lymphocytic Lymphoma Therapies- ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
For further information on the Small lymphocytic lymphoma Pipeline Therapeutics, reach out @ Small lymphocytic lymphoma Products Development [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Small Lymphocytic Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Small Lymphocytic Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Last Stage Products (Phase III)
* LOXO-305: Loxo Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Small Lymphocytic Lymphoma Key Companies
* Small Lymphocytic Lymphoma Key Products
* Small Lymphocytic Lymphoma - Unmet Needs
* Small Lymphocytic Lymphoma - Market Drivers and Barriers
* Small Lymphocytic Lymphoma - Future Perspectives and Conclusion
* Small Lymphocytic Lymphoma Analyst Views
* Small Lymphocytic Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=small-lymphocytic-lymphoma-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
